Remission Realized: Achieving Disease Control in Your Patients with Rheumatoid Arthritis - Episode 13
Outcomes of Class Switching vs Cycling TNF Inhibitors
Panelists discuss how switching to a biologic with a different mechanism of action can enhance clinical outcomes in patients with inadequate responses to tumor necrosis factor inhibitors.
Video content above is prompted by the following:
- What outcomes are associated with switching to a biologic with a different mechanism of action (MOA) rather than cycling a tumor necrosis factor inhibitor (TNFi)?
- Can you describe an anecdotal patient case in which the patient switched therapy to a different MOA? Did the switch happen after a few TNFis or after first TNFi
